NOCIL

- NOCIL Limited has allotted 18,150 equity shares of face value ₹10 each on 6th November 2026. - Shares were allotted upon the exercise of stock options under the Employee Stock Option Scheme-2007. - Exercise price is ₹84.05 per share, granted to Senior Management Personnel. - Total paid-up equity share capital increased from 16,70,24,930 shares (₹167,02,49,300) to 16,70,43,080 shares (₹167,04,30,800).

Current scenario - Q2FY27 revenue from operations stood at Rs.427 crores, registering a year-on-year growth of 33% and sequential growth of 6%. - EBITDA for Q2FY27 stood at Rs.36 crores, representing a growth of 61% YoY with margins at 8.4%. - H1FY27 revenue from operations stood at Rs.830 crores, up 26% YoY, and EBITDA stood at Rs.81 crores, up 54% YoY. - Volumes declined by 3% YoY and 7% sequentially in Q2 due to temporary supply side constraints and logistical challenges from geopolitical situations, which have now been addressed. Changes in trends - Higher raw material and utility costs (coal, gas, and sea freight) impacted conversion costs during the first half of the year. - Domestic tire demand benefited from consumption tailwinds following GST 2.0. Management Guidance & Outlook - Confident of closing FY27 towards the upper end of the previously indicated revenue range of Rs.1,400 crores to Rs.1,600 crores, with EBITDA margins of around 10%. - Expected volume growth for FY27 is maintained at 8% to 10% supported by domestic and international market traction. - Actively exploring opportunities for inorganic growth in the chemical space. Capex - Brownfield TDQ expansion at Dahej is progressing towards customer approvals, which are expected in Q3. - Work on the integrated specialty rubber chemicals project is progressing as planned, with total sanctioned capex of around Rs.130 crores being deployed across H2FY27 and FY28.

- NOCIL Limited informed the exchange regarding the availability of the audio recording for the investors and analyst conference call held on the operational and financial performance for the quarter and half year ended 30th September, 2026. - The audio recording has been uploaded to the company website for public access.

Q2 FY27 Consolidated Revenue ₹427Cr vs ₹321Cr (▲33% YoY) EBITDA ₹35Cr vs ₹25Cr (▲40% YoY) PAT ₹24Cr vs ₹12Cr (▲98% YoY) EBITDA Margin 8.2% vs 7.8% (▲40bps)

Q2 FY27 Consolidated Revenue ₹426.89Cr vs ₹320.56Cr (▲33% YoY) EBITDA ₹36.00Cr vs ₹22.32Cr (▲61% YoY) PAT ₹24.05Cr vs ₹12.12Cr (▲98% YoY) EBITDA Margin 8.43% vs 6.96% (▲147bps)

Concall Schedule Concall Date: Friday, October 30th, 2026 Concall Time: 11:30 AM IST

- NOCIL Limited granted 1,04,960 Performance Restricted Stock Units (PRSUs) under its Long Term Incentive Plan 2024 on 23rd September 2026. - The exercise price is ₹10 per share. - PRSUs vest in three years and can be exercised from five years after the grant date.

- NOCIL Limited announced the closure of its trading window for Designated Persons from September 30, 2026. - This is ahead of the Unaudited Financial Results for the quarter and half-year ended September 30, 2026. - The window will reopen 48 hours after the results declaration.

- Concall Schedule - Concall Date: 28th September 2026 - Concall Time: 02:00 pm onwards

- NOCIL received queries from NSE and BSE on September 9, 2026, regarding a spurt in trading volume. - The company clarified there is no undisclosed price-sensitive information and is compliant with SEBI (LODR) Regulations.

- NOCIL Limited announced the appointment of M/s Deloitte Haskins & Sells Chartered Accountants LLP as Statutory Auditors for a five-year term. - The term commences from the conclusion of the 65th Annual General Meeting (July-Aug 2027) until the 70th Annual General Meeting (FY 2031-32). - The appointment is subject to the approval of the members at the 65th AGM. - M/s Kalyaniwalla & Mistry LLP will continue as auditors until the 65th AGM, completing their second consecutive term.

- Q1 FY27 Consolidated Revenue from Operations ₹403 Cr (▲20% YoY) - Q1 FY27 Consolidated EBITDA ₹45 Cr (▲48% YoY), with EBITDA margin of 11.2% (▲210 bps YoY) - Q1 FY27 Consolidated PAT ₹28 Cr (▲61% YoY) - Volumes grew 9% YoY, though experienced a 3% sequential decline due to temporary supply-side and logistics issues. - FY27 revenue guidance is ₹1,400-₹1,600 Cr with an EBITDA in the region of 10%. - Anti-dumping duty approved on Sulphonamides (CBS and NS); positive recommendation for Pilflex 13 awaited government approval. - New TDQ plant trial production progressing well, with revenues expected from Q4 FY27. - Overall demand outlook for the tyre industry remains positive, despite near-term seasonal moderation.

- The audio recording of the Investors / Analyst conference call on the operational and financial performance for the quarter ended June 30, 2026, has been uploaded to NOCIL Limited's website. - The recording is accessible via the provided link.

- Consolidated Revenue ₹403Cr vs ₹335.83Cr (▲20% YoY) - EBITDA ₹45.14Cr vs ₹30.56Cr (▲47.7% YoY) - PAT ₹28Cr vs ₹17.39Cr (▲61% YoY) - EBITDA Margin 11.2% vs 9.1% (▲210bps)

- The 64th Annual General Meeting (AGM) of NOCIL Limited was held on August 3, 2026. - Members adopted the audited financial statements for the year ended March 31, 2026. - A dividend of Rs. 1.50/- per equity share was declared. - Re-appointments of directors and Executive Chairman, and appointments of new Independent Directors were approved.

- Members/Shareholders approved appointments and re-appointments of Directors at the 64th AGM held on 3rd August 2026. - Mr. Sanjiv Lal and Mr. Sabyaschi Patnaik appointed as Independent Directors for 5 years (7th May 2026 to 6th May 2031). - Mr. Hrishikesh A. Mafatlal re-appointed as Executive Chairman for 5 years (19th August 2026 to 18th August 2031). - The company affirmed that the appointed directors are not debarred by SEBI.

- The 64th Annual General Meeting (AGM) of NOCIL Limited was held on August 3, 2026. - All 7 resolutions proposed at the AGM were approved by the shareholders with an overwhelming majority. - Key approvals include the adoption of financial statements, declaration of a dividend on equity shares for FY26, re-appointment of Directors, and appointment of Independent Directors.

- Consolidated Revenue ₹403.02Cr vs ₹336.22Cr (▲19.87% YoY) - EBITDA ₹45.22Cr vs ₹30.58Cr (▲47.87% YoY) - PAT ₹27.76Cr vs ₹17.26Cr (▲60.83% YoY) - EBITDA Margin 11.22% vs 9.09% (▲213bps)